Sep 22, 2025, 06:33
Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways
Dr. Mukesh, Assistant Professor of Clinical Immunology and Rheumatology at King George’s Medical University (KGMU), posted on X:
”Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways
- APS affects 0.5% of the population but is a major cause of recurrent pregnancy loss (RPL), preeclampsia and FGR.
- Pathogenesis: “Two-hit model” → aPL antibodies trigger endothelial/placental dysfunction → thrombosis + insufficiency.
- Lupus anticoagulant (LA) = strongest predictor of poor outcomes.
- Standard of care: Low-dose aspirin (LDA) + LMWH → boosts live birth rates.
- Hydroxychloroquine (HCQ) reduces preterm birth and improves placental health in high-risk cases.
- Refractory APS? → Novel options: TNF-α inhibitors, complement blockers (eculizumab), nitric oxide modulators, statins.
- APS + SLE overlap = compounded risks → needs aggressive, multidisciplinary management.
- CAPS (catastrophic APS) = rare but lethal; pregnancy can trigger it (mortality ~36%).
- New 2023 ACR/EULAR criteria improve APS classification and risk stratification in pregnancy.
Bottom line: Early diagnosis, tailored therapy, and multidisciplinary care = better outcomes for mom and baby.”
Read the full review here.
Title: Antiphospholipid syndrome in pregnancy: a comprehensive literature review
Authors: Viorela Romina Murvai, Radu Galiș, Anca Panaitescu, Casandra Maria Radu, Timea Claudia Ghitea, Paula Trif, Miruna Onița-Avram, Alexandra Alina Vesa, Anca Huniadi

Stay updated with Hemostasis Today.
Alexandra Alina Vesa
Anca Huniadi
Anca Panaitescu
Antiphospholipid Syndrome
APS
Aspirin
BioMed Central
BMC
Casandra Maria Radu
Catastrophic APS
Health
Hematology
Hemostasis
Hemostasis Today
Heparin
Hydroxychloroquine
Immunology
in Pregnancy
King George's Medical University (KGMU)
LMWH
Low-Molecular-Weight Heparin
Lupus anticoagulant (LA)
Medicine
Miruna Onița-Avram
Mukesh
Paula Trif
Pregnancy
Radu Galiș
Recurrent Pregnancy Loss (RPL)
Rheumatology
thrombosis
Timea Claudia Ghitea
Viorela Romina Murvai
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall
-
Jun 10, 2026, 17:51Mariam Swidan: Some Red Blood Cells Can’t Handle Pressure
-
Jun 10, 2026, 17:49Ankit Mathur: Hosting ISBT Academy Day on Rare Donor Program in India
-
Jun 10, 2026, 17:48Shadi Tabibian: When Patients Bleed but Standard Testing Is Normal